Purchase this article with an account.
S. J. Driscoll, K. S. Klein, MD, M. Walsh, T. S. Hassan, MD, L. S. Halperin, MD, A. A. Castellarin, MD, D. Roth, MD, J. L. Prenner, MD; Multicenter Study of Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6185.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents.
Retrospective chart review.
We identified 15 cases of presumed endophthalmitis out of 30329 anti-VEGF injections (pegaptanib, bevacizumab and ranibizumab) over a one year time span. Mean time to diagnosis was 3.5 days. 46% of cases were culture positive. 10 patients returned to baseline vision, 2 lost between 3-5 lines of vision, 1 dropped from 20/30 to hand motions vision, and 2 became no light perception.
This large multicenter study revealed a presumed endophthalmitis incidence of 0.049% in over 30000 injections. 67% of patients returned to baseline vision while 20% had very poor outcomes.
This PDF is available to Subscribers Only